The Fox Focus Fall/Winter 2017 - Page 4

Research RESEARCH BRIEFS Fall/Winter 2017 Foundation-funded Companies Announce Deals to Advance Parkinson’s Therapies This summer, two companies became the latest examples of how the Foundation’s “de-risking” strategy of funding early-stage projects attracts larger investors to move Parkinson’s treatments forward. The Michael J. Fox Foundation (MJFF) granted nearly $2.5 million to Israeli biotech NeuroDerm between 2006 and 2013 for its pump-patch continuous delivery of levodopa/ carbidopa to prevent motor fluctuations, now in Phase III trials. In July, the company announced acquisition by Mitsubishi Tanabe Pharma Corporation for $1.1 billion. Another company, Prana Biotechnology, which received a $200,000 grant from MJFF in 2011 for pre-clinical work creating a drug targeting alpha- synuclein, is now partnering with Takeda Pharmaceuticals for a Phase I trial. 4 The Fox Focus